WO2005000286A1 - 疲労を回復又は軽減するための組成物、および当該組成物を備える医用デバイス - Google Patents
疲労を回復又は軽減するための組成物、および当該組成物を備える医用デバイス Download PDFInfo
- Publication number
- WO2005000286A1 WO2005000286A1 PCT/JP2004/009020 JP2004009020W WO2005000286A1 WO 2005000286 A1 WO2005000286 A1 WO 2005000286A1 JP 2004009020 W JP2004009020 W JP 2004009020W WO 2005000286 A1 WO2005000286 A1 WO 2005000286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- present
- medical device
- fatigue
- recovering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- composition for recovering or reducing fatigue Composition for recovering or reducing fatigue, and medical device provided with the composition
- the present invention relates to a composition for recovering or reducing fatigue, and more particularly, to a composition containing trans-2_hexenal and / or cis_3_hexenol. Furthermore, the present invention relates to a medical device comprising the above composition. Background art
- Green scent is a scent emitted from a mixture of a plurality of components, specifically, a complex scent generated from a mixture of eight components. Although the specific structures of these eight components are unknown, they are contained at different concentrations (for example, see Non-Patent Document 1).
- the "green scent” may affect endocrine hormone system, autonomic nervous system, and / or immune system in rats expressing Fos-like protein due to restraint stress. By doing so, expression of the Fos-like protein is suppressed (for example, see Non-Patent Document 2).
- Patent Document 1 A bath composition using cutting of xylem and branches and leaves of a cypress plant is known (for example, see Patent Document 1).
- Patent Document 1 describes "refreshing effect of each component such as fragrance eluted in edible and / or medicinal plants", but there is no specific description of the fragrance component.
- the present invention provides a composition having an effect of recovering or reducing fatigue, that is, an anti-fatigue effect, specifically, a composition for alleviating the symptoms of chronic fatigue syndrome and / or preventing karoshi.
- the purpose is to:
- the present inventors have conducted intensive studies on a substance having an effect of recovering or reducing fatigue that achieves the above object, that is, a substance having an anti-fatigue effect. As a result, trans-2-hexenal and Z or cis-3-hexenol were found to have an anti-fatigue effect, and the present invention was completed.
- composition of the present invention is characterized by containing trans_2_hexenal or cis-3_hexenol in order to solve the above problems.
- composition of the present invention preferably contains both trans_2_hexenal and cis_3_hexenol.
- composition of the present invention preferably relieves the symptoms of chronic fatigue syndrome.
- composition of the present invention preferably prevents overwork or overwork death.
- the composition of the present invention is aromatic, and the fragrance provides an anti-fatigue effect.
- composition of the present invention is preferably a fragrance, liquid detergent, solid detergent, cosmetic, bath composition, health and hygiene material, or oral composition.
- composition of the present invention can be taken orally.
- composition of the present invention is preferably a food.
- composition of the present invention is preferably in a form that enables eye drops or nasal drops.
- composition of the present invention is preferably in an inhalable form.
- composition of the present invention is preferably a pharmaceutical composition for recovering or reducing fatigue
- the medical device of the present invention is characterized by comprising the above composition.
- the medical device of the present invention is preferably a medical mask.
- the medical device of the present invention is preferably a medical mask applied to a patient suffering from hay fever.
- the composition preferably contains 0.5% by weight or less of trans_2_hexenal and / or cis_3-hexenol.
- the medical device of the present invention is preferably a device for inhalation aerosol used for treatment of airway diseases.
- the airway disease is preferably an inflammatory or obstructive airway disease.
- the inflammatory or obstructive airway disease is preferably asthma.
- FIG. 1 is a diagram showing five typical component waves of an acceleration pulse waveform, a-wave, b-wave, c-wave, d-wave, and e-wave.
- FIG. 2 shows the average response of ATMT obtained by the composition of the present invention or the comparative preparation 1 as a control. It is a graph which shows a time delay.
- FIG. 3 is a graph showing a change in wave height of a-wave among acceleration pulse waves obtained by the composition of the present invention or comparative preparation 1 as a control.
- FIG. 4 is a view showing a VAS test sheet used in Comparative Example 2. The figure shown here reflects the approximate actual scale, and the line segment is usually about 10 cm.
- FIG. 5 is a graph showing changes in VAS test results.
- FIG. 6 is a graph showing changes in NK activity.
- E means effector cells
- T means target cells
- numerical values indicate the ratio of each cell.
- FIG. 7 is a graph showing changes in blood DHEAS concentration.
- the term “fatigue” refers to "temporary physical and mental phenomena observed when a physical or mental load (so-called stress) is continuously applied. And / or reduced mental performance ". "Degraded performance” is intended to mean a qualitative or quantitative decline in physical and / or mental performance. As used herein, “anti-fatigue effect” is intended to have an effect of relieving fatigue or an effect of reducing fatigue.
- chronic fatigue syndrome refers to a condition in which a healthy social life cannot be achieved due to chronic fatigue of unknown cause. This is a disease concept designed to elucidate the etiology and Z or pathological condition (see Japanese Society of Internal Medicine, 81: 573-582 (1992)). Chronic fatigue syndrome often develops suddenly when people have been living healthy and have suffered a cold or the like. In chronic fatigue syndrome, severe fever, headache, lymphadenopathy, muscular pain, weakness, impairment in thinking or concentration, depression, and sleep disorders may occur over a long period of time with severe unexplained general malaise. To be observed. As used herein, "alleviating the symptoms of chronic fatigue syndrome” means removing, reducing and / or ameliorating one or more of the symptoms of such chronic fatigue syndrome. Figure.
- overwork death is due to overwork in prolonged overcrowding. Intended to die suddenly. Overwork death is widely known in modern Japan and attracts attention as a major social problem. According to the medical doctor, Tetsunojo Uehata, director of the Office of Adults at the National Public Health Institute, said the name of overwork death was ⁇ excessive work caused high blood pressure or arteriosclerosis, resulting in cerebral hemorrhage, A condition that results in permanent inability to work or death due to subarachnoid hemorrhage, cerebrovascular disease such as cerebral infarction, ischemic heart disease such as myocardial infarction, or acute cardiac death.
- composition according to the present invention exhibits an anti-fatigue effect, through which fatigue or karoshi can be prevented.
- the composition of the present invention may be a pharmaceutical composition.
- Trans-2-xenal and cis-3xenol can be easily prepared from readily available starting materials (for trans-2-hexenal, see A. Hatanaka and M. Ohno, Agric. Biol. Chem. 25, 7 (1961), cis-3-hexenol, see Japanese Patent Application Laid-Open No. 55-102531 (published August 5, 1980).
- composition according to the present invention may contain any one of the above components, or may contain both of them. Also exerts anti-fatigue effect.
- the total content of the trans 2 xenal and cis 3 xenol compounds in the composition according to the present invention may vary depending on the form and application site of the composition, from 0.01 to 100% by weight, preferably from 0.1 to 100% by weight. — 80% by weight, more preferably 0.130% by weight. When applied to a site near the nose, the content is preferably 0.12% by weight, and most preferably 0.11% by weight, considering discomfort based on the intensity of the scent.
- the composition according to the present invention is aromatic, and the fragrance provides an anti-fatigue effect.
- the composition according to the present invention can be used as a fragrance, a liquid detergent, a solid detergent, a cosmetic, a bath composition, a health and hygiene material, an oral composition, a food, and the like.
- fragrances such as indoor fragrances and deodorants
- liquid or solid detergents such as dishwashing detergents, laundry detergents, and daily detergents
- washings such as stones, shampoos, and rinses.
- Hair cosmetics such as cleansing cosmetics, hair coloring, hair styling, and hair restoration, basic cosmetics such as cream, lotion, eau de cologne, packs, makeup cosmetics such as whitening, foundation, blusher, etc., and aromatic cosmetics such as perfume and colon
- Cosmetics such as lip cosmetics such as tanning, sunscreen cosmetics, lipsticks and lip balms; various bath compositions such as bath oil; health and hygiene materials such as clean tissue; oral compositions such as toothpaste and mouthwash; And incense.
- composition according to the present invention is preferably in a form that can be orally ingested, and for example, may be added to food.
- composition according to the present invention When the composition according to the present invention is prepared into daily necessities such as foods and fragrances, various components and additives used in the foods and daily necessities are added to the composition according to the present invention as necessary. It is arbitrarily selected and mixed within a range that does not impair the anti-fatigue effect.
- the binder may be, for example, hydroxyethylcellulose, hydroxypropinoresenololose, hydroxypropinolemethinoresenorelose, canoleboxymethinoresenolle sodium sodium, polybutylporolidone, or Excipients such as polybutyl alcohol; for example, lactose, sucrose, D-mannitol, oligosaccharides, starch, gelatin, crystalline cellulose, light caffeic anhydride, etc .; and lubricants, for example, magnesium stearate.
- disintegrants for example, starch, carboxycellulose, carboxymethylcellulose Calcium, croscarmellose sodium, sodium carboxymethyl starch, etc.
- bases according to the preparation type eg, ointment bases (eg, hydrocarbon bases such as petrolatum, liquid paraffin, wax, etc., cetanol), higher fatty acid esters, etc.)
- Gel bases eg, carboxybutyl polymer, polyoxyethylene polyoxypropylene block copolymer, gum etc.
- oily bases eg, vegetable oils such as olive oil, soybean oil, sesame oil, cottonseed oil, propylene glycol
- solvents, water, oily bases, solubilizers, surfactants, suspending agents, emulsifiers, isotonic agents, buffers, etc. can be used as bases.
- a preservative, an antioxidant, a sweetener, a sour agent, a coloring agent, a flavor, and the like may be added to the composition according to the present invention, if necessary.
- composition according to the present invention are illustrated below, but are not limited to these components.
- saccharide examples include glucose, fructose, galactose, mannose, ribose, ribulose, arabinose, xylose, lyxose, deoxyribose, maltose, trenperose, sucrose, cellobiose, ratatose, pullulan, lactulose, raffinose and multi And tol, and salts thereof.
- Examples of the thickener include polysaccharides and derivatives thereof (gum arabic, karaya gum, xanthan gum, carob gum, guar gum, guayata fat, quince seed, dalman gum, tragant, benzoin gum, locust bean gum, casein, agar, Alginic acid, dextrin, dextran, carrageenan, gelatin, collagen, pectin, starch, polygalacturonic acid, chitin or a derivative thereof, chitosan or a derivative thereof, elastin, heparin heparinoid, heparin sulfate, heparan sulfate, hyanoleronate, Chondroitin sulfate, etc.), ceramide, senorelose derivatives (methinoresenorelose, ethinoresenorelose, hydroxyethinoresenorelose, hydroxypropinoresenor
- surfactant examples include polyoxyethylene (POE) -polyoxypropylene (POP) block copolymer (for example, poloxamer 407, poloxamer 235, poloxamer 188, etc.), POE (20) sorbitan monolaurate ( POE sorbitan fatty acid esters such as polysorbate 20), POE (20) sorbitan monooleate (polysorbate 80), POE (60) POE hardened castor oil such as hydrogenated castor oil, POE (9) POE alkyl such as lauryl ether Ethers, POE (20) POP (4) P ⁇ E POP alkyl ethers such as cetyl ether, P ⁇ ⁇ ⁇ E (10) POE alkyl phenyl ethers such as nonyl phenyl ether Ionic surfactants: glycine type such as alkyldiaminoethyldaricin, betaine acetate type such as betaine lauryldi
- composition according to the present invention preferably has its active ingredient, trans-12-hexenal and / or cis-3_hexenol, acting as a fragrance on the nasal cavity to exhibit its medicinal properties. No.
- the composition according to the present invention is preferably in a form that allows eye drops or nasal drops.
- the composition according to the present embodiment is preferably used as a mixture with eye drops or nasal drops generally used for medical purposes.
- the composition according to the present invention is preferably in an inhalable form.
- the composition according to this embodiment comprises an inhalable aerosol Preferably, it is a composition. More preferably, the composition according to the present embodiment is preferably used in combination with an inhalable drug generally used for medical purposes.
- the composition according to the present invention can reduce or recover fatigue by reducing or reducing physical or mental load, that is, stress.
- Diseases that cause stress include, for example, inflammatory or obstructive airway diseases (eg, asthma, acute lung injury (ALI), adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, chronic bronchitis and Airway or lung diseases including emphysema (COPD, COAD or COLD), bronchiectasis and other medications (exacerbated airway hyperresponsiveness as a result of other inhaled medications). But not limited). Therefore, the composition according to the present invention is more effective when used with an agent for treating or ameliorating an inflammatory or obstructive airway disease such as asthma.
- inflammatory or obstructive airway diseases eg, asthma, acute lung injury (ALI), adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, chronic bronchitis and Airway or lung diseases including emphysema (COPD, COAD
- the composition according to the present invention is preferably in an inhalable form to be administered by inhalation.
- the inhalable form of the composition according to the invention is, for example, a sprayable composition such as an aerosol comprising the active ingredient in solution or dispersion, or aqueous, organic or aqueous It can be a nebulizable composition comprising a dispersion of the active ingredient in an organic medium.
- a preferred aerosol composition for use as an inhalable form of the composition according to the present invention is a propellant solution or dispersion that can be selected from any propellant (propellant) known in the art. It may contain active ingredients.
- propellants include hydrocarbons such as n-propane, n-butane or isobutane or mixtures of two or more thereof, and halogen-substituted hydrocarbons such as fluorinated methane, ethane, propane, Butane, cyclopropane or cyclobutane, especially 1,1,1,2-tetrafluoroethane (HF
- the aerosol compositions When the active ingredient is present in suspension in the propellant, i.e., in the form of particles dispersed in the propellant, the aerosol compositions also include lubricants and surfactants known in the art. It may include lubricants and surfactants that may be selected from. Other suitable aerosol compositions include surfactant-free or substantially surfactant-free aerosol compositions. It is. The aerosol composition, based on the weight of the propellant up to about 5 wt%, For example, 0.5 002- 5 weight 0/0, 0.
- one 2 wt 0/0 may include 0. 5-2 wt%, or 0.1 5-1% by weight of active ingredient.
- Lubricants and surfactants, if present, can be in amounts up to 5% and 0.5% by weight of the aerosol composition, respectively.
- the aerosol composition may also include a co-solvate, such as ethanol, in an amount up to 30% by weight of the composition, particularly for administration by a pressurized metered-dose inhaler.
- the active ingredient of the composition according to the invention has an average particle size of up to about 10 ⁇ m, for example, 0.1-5 ⁇ m, preferably 115 ⁇ m. obtain.
- the solid support will usually have a maximum particle size of up to 300 zm, preferably up to 200 zm, conveniently having an average particle size of 40-100 zm, for example 50-75 zm.
- the particle size of the active ingredient, and the particle size of the solid carrier when present in the dry powder composition can be determined by conventional methods, for example, by air jet mill, ball mill or vibrator-mill, microprecipitation, spray drying. It can be comminuted to the desired level by polishing, lyophilization or recrystallization from supercritical media.
- the present invention further provides a medical device comprising the composition according to the present invention.
- the term "medical device” includes a composition according to the present invention, and a disease (preferably, fatigue) exhibited by a subject based on the pharmacological effect of the composition. Or devices for reducing or treating stress).
- the medical device according to the present invention is preferably a device for aerosol inhalation used for treatment of the above-mentioned airway diseases.
- the medical device according to the present embodiment includes the composition according to the present invention. It is preferable that the medical device according to the present embodiment further includes a medicine for treating an airway disease.
- MMI metered dose inhaler
- Another type of device is a dry bow (See, for example, US Pat. Nos. 5,775,320 and 5,740,794, which are incorporated herein by reference.)
- Yet another type of aerosol dispensing device extrudes a formulation through porous membrane tissue (see, for example, US Pat. Nos. 5,554,646 and 5,522,385, which are incorporated herein by reference). Which is incorporated herein by reference)).
- the medical device according to the present invention is an inhaler
- the inhaler has a composition such as 10 100 ⁇ l, for example, 25 50 ⁇ l.
- An aerosol vial provided with a valve adapted to deliver a measured dose of an object, a device known as a metered dose inhaler. Suitable procedures for including such aerosol vials and aerosol compositions under pressure are known to those skilled in the art of inhalation therapy.
- the inhalation device may be known as a known nebulizer, for example A mechanical device such as a conventional pneumatic nebulizer, such as an air jet nebulizer, or an ultrasonic nebulizer; or a hand-held nebulizer, which may contain as much as 50 ml, usually 110 ml of dispersion.
- a conventional pneumatic nebulizer such as an air jet nebulizer, or an ultrasonic nebulizer
- a hand-held nebulizer which may contain as much as 50 ml, usually 110 ml of dispersion.
- the inhalation device may, for example, be a capsule or a blister containing a dry powder containing a dose unit of the active ingredient of the composition according to the invention.
- Dry powder inhalation device for the delivery of dry powders from, or multidose dry powder inhalation (MDPI) for the delivery of 3 to 25 mg of dry powder containing, for example, a dosage unit of the active ingredient of the composition according to the invention ) Device.
- MDPI multidose dry powder inhalation
- Suitable dry powder inhalers are well known in the art.
- a suitable device for the delivery of encapsulated dry powder is that described in US3991761, while a suitable MDPI device is that described in WO97 / 20589.
- the medical device according to the present invention is a medical mask.
- Medical masks are not only effective as remedies for the above-mentioned respiratory tract diseases, but also effective for subjects suffering from “hay fever”, which has recently become a problem. Since hay fever prevents normal daily life, patients suffering from hay fever are clearly stressed, and as a result, accumulate fatigue based on their mental burden. Subject suffering from "hay fever”
- a person can not only exacerbate the symptoms of "hay fever” but also recover or reduce stress caused by "hay fever” and fatigue based on the stress. can do.
- the medical device according to the present embodiment is preferably a medical mask including a container (preferably, a breathable mesh bag) containing the composition according to the present invention.
- the medical device according to the present embodiment is preferably a medical mask provided with a gauze containing the composition according to the present invention.
- the composition according to the present invention is preferably applied to gauze.
- the composition according to the present invention is preferably in a soluble form for penetration into gauze.
- the present invention is the result of a study on the needs of consumers of the Ministry of Education, Culture, Sports, Science and Technology's Science and Technology Promotion Coordination "Research on molecular and neural mechanisms of fatigue and fatigue and its defense”.
- Comparative Formulation 1 has the same composition as the composition of the present invention except that it does not contain trans 2-hexenal and cis 3-hexenol.
- ATMT is a test used to evaluate aging phenomena and to screen for early stage dementia.
- a visual search response task is performed in which the user presses up to one-hundred and twenty-five numbers presented on the touch display.
- TMT a task of drawing a line of 125 randomly arranged numbers in a single stroke
- measure the search response time for each target number It is also possible to rearrange all the target numbers for each reaction, or to delete the reacted target numbers and generate new target numbers. By performing these steps, it is possible to evaluate the increase in mental fatigue observed during the task, or the degree of utilization of working memory to increase search efficiency.
- Acceleration pulse waves are used for aging or physical condition evaluation of blood vessels (see Japanese Patent Application Laid-Open No. 2002-238867 (published August 27, 2002)). Acceleration pulse waves are obtained by further differentiating the first derivative waveform to assist in the analysis of pulse waves (Yuji Sano, Yukio Kataoka, Tadashi Ikuyama, Mitsuaki Wada, Hirotaka Konno, Kyohei Kawamura, Tsuyoshi Watanabe , Akiko Nishida, and Hiroshi Koyamauchi: Evaluation of Blood Circulation by Acceleration Pulse Wave and Its Application, Occupational Science, 61 (3), 129-143 (1985)).
- Acceleration pulse waves are considered to show blood circulation dynamics by differentiating the pulse wave twice to emphasize the inflection point and facilitate the evaluation of the waveform.
- the sharper the inflection point of the original waveform the greater the amplitude of the inflection point of the second derivative waveform (Meisuke Suzuki: Physiological function test pulse wave, acceleration pulse wave, modern medicine, 23 (1), 61—65 (1991)). Therefore, it is considered that the acceleration pulse wave facilitates the recognition and measurement of the waveform pattern at the inflection point, and is therefore considered to be more suitable for studying the relationship with physiological functions and hemodynamics.
- the acceleration pulse waveform is the waveform during the systole of the heart, and five component waves, a-wave, b-wave, c-wave, d-wave, and e-wave, are observed (Fig. 1).
- the vertical axis in Fig. 1 represents the wave height (amplitude (mV)), which is thought to change with fatigue or stress (the horizontal axis is time (seconds)).
- the change in the wave height of the a-wave was measured, and the change in the wave height of the a-wave was evaluated by measuring the acceleration pulse wave before and after the mental workload.
- the change of each symptom was examined by applying the composition of the present invention prepared in Example 1 to eight patients (CFS patients) diagnosed with chronic fatigue syndrome.
- the use conditions are as follows: for about 10 minutes at a time, 3 to 7 times a day, by inhaling the scent of the composition of the present invention for 12 weeks to change clinical symptoms, VAS (visual analogue scale), The symptoms of chronic fatigue syndrome were evaluated using NK activity and DHEAS (dehydroepiandrosterone sulfate) in blood as indices. This study was conducted in patients who had been treated for a long period of time, such as administration of vitamins or Kampo medicines, but who did not alleviate the symptoms of chronic fatigue syndrome, and underwent continuous treatment. I went in.
- VAS is a method in which a test subject is shown a piece of paper on which reference expressions are written at both ends of a line segment, and which part of the line segment the subject wants to measure corresponds to. This is a method of checking and evaluating. By calculating the ratio of the length from the left end to the right end to the total length, the VAS can obtain quantitative results for the question items, and as a result, the results from many subjects can be obtained. This method has the advantage that processing such as averaging can be performed.
- Fig. 4 shows the VAS test paper used in this example.
- NK activity refers to the strength of the action of NK (natural killer) cells to attack cancer cells and the like. NK activity is generally an indicator of immunity, or a finger of chronic fatigue syndrome. It is widely used as a target. It is also known that NK activity is reduced in patients with CFS (see History of Medicine, Vol. 204, No. 5, 381-386).
- peripheral blood mononuclear cells of a subject and cancer cells labeled with 51 Cr are used.
- 51 Cr is a substance that has the property that it is not released from cells during the life of the labeled cancer cell, but is released from the cell when the cancer cell dies.
- the labeled cancer cells and peripheral blood mononuclear cells are mixed, and the amount of free label substance (A value: corresponding to the number of cancer cells killed by NK cells) is measured after a certain period of time.
- the NK activity (A / BX 100 (A / BX 100 (%)) is calculated by dividing the A value by the amount of label released from the cells when all cancer cells are destroyed (B value: equivalent to the total number of cancer cells). ./.)) Is required. Larger values of NK activity indicate that more cancer cells have been killed.
- Heparin-added peripheral blood is separated from effector cells using specific gravity centrifugation (Conray-Ficll: d-1.077), cells are washed with PBS (twice), and then 10% FBS The RPMI1640 culture solution supplemented with the mixture was added to the cells, and the cell number was adjusted to 1 ⁇ 10 6 cells / ml.
- the suspension subcultured cells (K-562 cells) are collected by centrifugation, 50-100 ⁇ Ci of 51 Cr-sodium chromate is added to the cells, and the cells are cultured at 37 ° C for 1 hour. Then, the cells were washed with PBS (twice), and a RPMI1640 culture solution supplemented with 10% FBS was added thereto to adjust the cell number to 1 ⁇ 10 6 cells / ml.
- Replenished RPMI 1640 cultures and effector cells (E / T 20) were dispensed to obtain experimental release values. Then, the mixture was centrifuged at 800 rpm for 5 minutes in a plate centrifuge, and cultured for 3.5 hours in a 5% CO incubator.
- the culture supernatant was collected from each well, the value of released 51 Cr was measured using a ⁇ -scintillation counter, and the NK activity was calculated using the following equation.
- DHEAS dehydroepiandrosterone sulfate
- composition of the present invention About 2 weeks after the start of application of the composition of the present invention, a decrease in general anxiety and tension, a reduction in muscle pain and arthralgia, etc. were observed, as well as a reduction in general malaise. At week 7, clinical symptoms improved in all eight cases.
- NK activity was clearly increased under any cell ratio condition compared to before the start of application of the composition of the present invention (FIG. 6). This indicates that trans-2-hexenal and cis-13-hexenol have the ability to alleviate the symptoms of chronic fatigue syndrome.
- Blood DHEAS levels increased 12 weeks after the start of application of the composition of the present invention compared to before the start of application of the composition of the present invention (FIG. 7). This is trans_2_hexenal and It shows that cis-13 xenol has a function to alleviate the symptoms of chronic fatigue syndrome.
- the use of the anti-fatigue composition of the present invention can improve the quality of daily life and can contribute to preventive medicine, which has attracted attention due to the problem of rising medical costs.
- chronic fatigue syndrome can be treated only by preventing overwork or death from overworking busy modern people, it can greatly contribute to solving problems caused by fatigue.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Detergent Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005511060A JP4422103B2 (ja) | 2003-06-27 | 2004-06-25 | 疲労を回復又は軽減するための組成物、および当該組成物を備える医用デバイス |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-185152 | 2003-06-27 | ||
JP2003185152 | 2003-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005000286A1 true WO2005000286A1 (ja) | 2005-01-06 |
Family
ID=33549643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009020 WO2005000286A1 (ja) | 2003-06-27 | 2004-06-25 | 疲労を回復又は軽減するための組成物、および当該組成物を備える医用デバイス |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4422103B2 (ja) |
WO (1) | WO2005000286A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006036726A (ja) * | 2004-07-29 | 2006-02-09 | Akikazu Hatanaka | トイレタリー製品 |
JP2006248921A (ja) * | 2005-03-08 | 2006-09-21 | Nivea Kao Kk | 発汗抑制剤 |
JP2007162188A (ja) * | 2005-12-16 | 2007-06-28 | Chuo System Giken:Kk | 睡眠導入剤及び睡眠導入具 |
JP2007308435A (ja) * | 2006-05-19 | 2007-11-29 | Pokka Corp | 脳機能改善剤及びそれを含有する脳機能改善組成物 |
JP2009108009A (ja) * | 2007-10-31 | 2009-05-21 | Kyoto Univ | 抗酸化酵素誘導剤 |
JP2016008955A (ja) * | 2014-06-26 | 2016-01-18 | 花王株式会社 | 疲労抑制剤の探索方法 |
JP2018179603A (ja) * | 2017-04-06 | 2018-11-15 | 高砂香料工業株式会社 | 心理、神経、内分泌、免疫指標を用いた香りの生理心理効果の評価方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06172781A (ja) * | 1992-09-25 | 1994-06-21 | Takasago Internatl Corp | 鎮静効果を与える香料改質剤 |
JP2000086478A (ja) * | 1998-09-11 | 2000-03-28 | Shiseido Co Ltd | 気化吸引用鎮静剤及びそれを有効成分とする鎮静香料組成物 |
JP2000355545A (ja) * | 1999-06-10 | 2000-12-26 | Karita Takahisa | 睡眠補充および/または導入用精油組成物および睡眠補充および/または導入剤 |
JP2001000141A (ja) * | 1999-03-01 | 2001-01-09 | Success:Kk | 杉葉抽出液の製法 |
JP2001019992A (ja) * | 1999-07-09 | 2001-01-23 | Shiseido Co Ltd | 高揚剤及び高揚香料組成物 |
-
2004
- 2004-06-25 WO PCT/JP2004/009020 patent/WO2005000286A1/ja active Application Filing
- 2004-06-25 JP JP2005511060A patent/JP4422103B2/ja not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06172781A (ja) * | 1992-09-25 | 1994-06-21 | Takasago Internatl Corp | 鎮静効果を与える香料改質剤 |
JP2000086478A (ja) * | 1998-09-11 | 2000-03-28 | Shiseido Co Ltd | 気化吸引用鎮静剤及びそれを有効成分とする鎮静香料組成物 |
JP2001000141A (ja) * | 1999-03-01 | 2001-01-09 | Success:Kk | 杉葉抽出液の製法 |
JP2000355545A (ja) * | 1999-06-10 | 2000-12-26 | Karita Takahisa | 睡眠補充および/または導入用精油組成物および睡眠補充および/または導入剤 |
JP2001019992A (ja) * | 1999-07-09 | 2001-01-23 | Shiseido Co Ltd | 高揚剤及び高揚香料組成物 |
Non-Patent Citations (2)
Title |
---|
HATAKANA A.: "Midori no kaori to hito-saikin no 2.3 no kenkyu kara", FOODS & FOOD INGRED., J. JPN. JN., no. 185, 2000, pages 57 - 59, XP002984959 * |
HATANAKA A.: "Shokubutsu kigen no 'midori no kaori' no hatsugen to seiriteki igi no kaimei ni kansuru kenkyu", NIPPON NOGEIKAGAKU KAISHI, vol. 67, no. 10, 1993, pages 1391 - 1398, XP002984958 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006036726A (ja) * | 2004-07-29 | 2006-02-09 | Akikazu Hatanaka | トイレタリー製品 |
JP2006248921A (ja) * | 2005-03-08 | 2006-09-21 | Nivea Kao Kk | 発汗抑制剤 |
JP2007162188A (ja) * | 2005-12-16 | 2007-06-28 | Chuo System Giken:Kk | 睡眠導入剤及び睡眠導入具 |
JP2007308435A (ja) * | 2006-05-19 | 2007-11-29 | Pokka Corp | 脳機能改善剤及びそれを含有する脳機能改善組成物 |
JP2009108009A (ja) * | 2007-10-31 | 2009-05-21 | Kyoto Univ | 抗酸化酵素誘導剤 |
JP2016008955A (ja) * | 2014-06-26 | 2016-01-18 | 花王株式会社 | 疲労抑制剤の探索方法 |
JP2018179603A (ja) * | 2017-04-06 | 2018-11-15 | 高砂香料工業株式会社 | 心理、神経、内分泌、免疫指標を用いた香りの生理心理効果の評価方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4422103B2 (ja) | 2010-02-24 |
JPWO2005000286A1 (ja) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4542300B2 (ja) | ヒアルロン酸蓄積促進剤 | |
JP5661994B2 (ja) | 抗ストレス・疲労防止、肌のキメ改善又はシワ改善・防止効果を有する組成物又は内服剤 | |
RU2745440C2 (ru) | Способы и композиции для лечения ожирения, предотвращения прибавки массы, содействия снижению массы, содействия похудению или лечения или предотвращения развития диабета | |
PL186017B1 (pl) | Zastosowanie ekstraktu z niefotosyntetyzującej bakterii nitkowatej oraz kompozycja zawierająca takiekstrakt | |
JP5599730B2 (ja) | 免疫細胞の活性化閾値を上昇させる物質 | |
JP4286513B2 (ja) | 抗老化用組成物 | |
JP2023126479A (ja) | グルコースの促進性輸送における使用のためのペプチド | |
JP2010520232A (ja) | 玄参抽出物を含有する外用剤組成物及びその皮膚保湿化粧料としての用途 | |
JPH10120583A (ja) | 抗アレルギー剤、ケミカルメディエーター遊離抑制剤及びこれを含有する抗アレルギー性化粧料,医薬品並びに食品 | |
JP4422103B2 (ja) | 疲労を回復又は軽減するための組成物、および当該組成物を備える医用デバイス | |
KR102159427B1 (ko) | 지방 감소를 위한 미용적 방법 및 치료적 용도 | |
JP2013533308A (ja) | ニコチン酸アデニンディヌクレオチドリン酸又はその誘導体を含む薬学又は化粧料組成物 | |
JP2018528259A (ja) | 成長促進性ペプチドおよびその使用 | |
JP7475018B2 (ja) | 皮膚外用組成物 | |
CN115671148B (zh) | 一种海木耳萃取物及其用途 | |
WO2022168939A1 (ja) | セラミド合成酵素遺伝子発現促進剤、肌質改善剤、肌質改善用機能食品及び化粧料並びにジペプチドの使用方法 | |
CN103458928B (zh) | (r)-1,2-丙二醇用作治疗性冷却剂组合物中的溶剂 | |
EP3636266A1 (en) | Agent for inhibiting skin trouble and composition for inhibiting skin trouble | |
EP3995143A1 (en) | Composition for preventing or treating rheumatoid arthritis, comprising snake venom | |
KR20150057888A (ko) | 패 추출물을 포함하는 항비만 및 셀룰라이트 감소용 조성물 | |
JP7217085B2 (ja) | ロイシン誘導体、それを含む組成物及びその用途 | |
TW201309314A (zh) | 丹參組成物在製備用於冠心病二級預防的藥物中的用途 | |
JP6656890B2 (ja) | フィラグリン産生促進剤 | |
KR20010086473A (ko) | 류코트리엔 생성 저해활성을 가지는 정유 성분 | |
KR102625903B1 (ko) | 네오판에폭시돈 또는 이소판에폭시돈 화합물을 유효성분으로 포함하는 미세먼지로 인한 호흡기 질환 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511060 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |